BR112012011792A2 - "compostos e métodos para modulação de quinases, e indicações para os mesmos" - Google Patents
"compostos e métodos para modulação de quinases, e indicações para os mesmos"Info
- Publication number
- BR112012011792A2 BR112012011792A2 BR112012011792A BR112012011792A BR112012011792A2 BR 112012011792 A2 BR112012011792 A2 BR 112012011792A2 BR 112012011792 A BR112012011792 A BR 112012011792A BR 112012011792 A BR112012011792 A BR 112012011792A BR 112012011792 A2 BR112012011792 A2 BR 112012011792A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- methods
- compounds
- raf
- protein kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
compostos e métodos para modulação de quinases, e indicações para os mesmos. são descritos compostos e sais dos mesmos, formulações dos mesmos, conjugados dos mesmos, derivados dos mesmos, formas dos mesmos, e aplicações dos mesmos. em alguns aspectos e modalidades, os compostos descritos ou sais dos mesmos, formulações dos mesmos, conjugados dos mesmos, derivados dos mesmos, formas dos mesmos são ativos sobre no mínimo uma proteína quinase raf. em alguns aspectos e modalidades, os compostos descritos são ativos na inibição da proliferação de uma linhagem de células mutantes ras. também são descritos métodos de aplicação dos mesmos para tratar doenças e condições, incluindo doenças e condições associadas com atividade de proteína quinase mutante b-raf v600e, incluindo melanoma, glioma, gliobastoma multiforme, astrocitoma pilocítico, câncer colorretal, câncer da tiróide, câncer pulmonar, câncer de ovário, câncer de próstata, câncer de fígado, câncer da vesícula biliar, tumores estromais gastrointestinais, câncer do trato biliar, e colangiocarcinoma. também são descritos métodos de aplicação dos mesmos para tratar doenças e condições, incluindo doenças e condições associadas com atividade de proteína quinase c-raf-1, incluindo dor aguda, dor crônica ou doença do rim policístico.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26251009P | 2009-11-18 | 2009-11-18 | |
US38331010P | 2010-09-15 | 2010-09-15 | |
PCT/US2010/057293 WO2011063159A1 (en) | 2009-11-18 | 2010-11-18 | Compounds and methods for kinase modulation, and indications therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012011792A2 true BR112012011792A2 (pt) | 2015-10-13 |
Family
ID=44060002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012011792A BR112012011792A2 (pt) | 2009-11-18 | 2010-11-18 | "compostos e métodos para modulação de quinases, e indicações para os mesmos" |
Country Status (20)
Country | Link |
---|---|
US (2) | US8673928B2 (pt) |
EP (1) | EP2501236B1 (pt) |
JP (2) | JP2013511541A (pt) |
KR (1) | KR20120097512A (pt) |
CN (2) | CN105906631A (pt) |
AU (2) | AU2010321883A1 (pt) |
BR (1) | BR112012011792A2 (pt) |
CA (1) | CA2781287C (pt) |
CL (1) | CL2012001303A1 (pt) |
CO (1) | CO6551689A2 (pt) |
ES (1) | ES2627911T3 (pt) |
IL (1) | IL219567A0 (pt) |
MA (1) | MA33811B1 (pt) |
MX (1) | MX2012005827A (pt) |
MY (1) | MY156210A (pt) |
NZ (1) | NZ599872A (pt) |
PE (1) | PE20121335A1 (pt) |
RU (1) | RU2012125070A (pt) |
SG (1) | SG10201407718WA (pt) |
WO (1) | WO2011063159A1 (pt) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
SG183036A1 (en) | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
MX349923B (es) | 2009-04-03 | 2017-08-21 | Hoffmann La Roche | Composiciones del ácido propano-1-sulfónico {3-[5-(4-cloro-fenil)- 1h-pirrolo [2,3-b]-piridina-3-carbonil]-2,4-difluoro-fenil]-amida y el uso de las mismas. |
ES2633317T3 (es) | 2009-11-06 | 2017-09-20 | Plexxikon, Inc. | Compuestos y métodos para la modulación de quinasas, e indicaciones para ello |
BR112012011792A2 (pt) | 2009-11-18 | 2015-10-13 | Plexxikon Inc | "compostos e métodos para modulação de quinases, e indicações para os mesmos" |
RU2012131373A (ru) | 2009-12-23 | 2014-01-27 | Плексксикон, Инк. | Соединения и способы модулирования киназы, а также показания для такого модулирования |
TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
MY162950A (en) * | 2011-02-07 | 2017-07-31 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
RU2631487C2 (ru) | 2011-05-17 | 2017-09-22 | Плексксикон Инк. | Модуляция киназ и показания к её применению |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
WO2013169531A1 (en) | 2012-05-09 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Methods for making oxetan-3-ylmethanamines |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
LT3495367T (lt) | 2012-06-13 | 2021-02-25 | Incyte Holdings Corporation | Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai |
WO2014018888A1 (en) * | 2012-07-26 | 2014-01-30 | Confluence Life Sciences Inc. | 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as tak1 inhibitors in disease treatment |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
MY174339A (en) | 2012-08-13 | 2020-04-09 | Novartis Ag | 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions |
CN103626765B (zh) * | 2012-08-27 | 2016-08-10 | 广东东阳光药业有限公司 | 取代的氮杂吲哚化合物及其盐、组合物和用途 |
ES2889757T3 (es) | 2012-09-06 | 2022-01-13 | Plexxikon Inc | Compuestos y procedimientos para la modulación de quinasas e indicaciones para estos |
CN104781260A (zh) * | 2012-09-26 | 2015-07-15 | 拜耳制药股份公司 | 用于治疗过度增殖性障碍的取代的吲唑-吡咯并嘧啶 |
EP2900671A1 (en) * | 2012-09-26 | 2015-08-05 | Bayer Pharma Aktiengesellschaft | Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
NZ711896A (en) | 2012-12-21 | 2018-04-27 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
AU2014233437B2 (en) | 2013-03-15 | 2018-07-26 | Opna Immuno Oncology, SA | Heterocyclic compounds and uses thereof |
MY181497A (en) | 2013-04-19 | 2020-12-23 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
KR20160013028A (ko) | 2013-05-30 | 2016-02-03 | 플렉시콘, 인코퍼레이티드 | 키나제 조정을 위한 화합물 및 그에 대한 적응증 |
KR102318727B1 (ko) * | 2013-07-31 | 2021-10-28 | 노파르티스 아게 | 1,4-이치환된 피리다진 유사체 및 smn-결핍-관련 상태를 치료하기 위한 그의 용도 |
WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
AR101106A1 (es) | 2014-07-02 | 2016-11-23 | Pharmacyclics Llc | Inhibidores de tirosina quinasa de bruton |
CA2961356C (en) | 2014-09-15 | 2023-03-07 | Plexxikon Inc. | Heterocyclic compounds and their uses in modulating bromodomain and for treating diseases or conditions relevant thereto |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
AU2016209046A1 (en) | 2015-01-23 | 2017-07-20 | Aclaris Therapeutics, Inc. | Heterocyclic ITK inhibitors for treating inflammation and cancer |
WO2016134320A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
WO2016164641A1 (en) | 2015-04-08 | 2016-10-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
ES2774178T3 (es) | 2015-05-06 | 2020-07-17 | Plexxikon Inc | Síntesis de derivados de 1h-pirrolo[2,3-B] piridina que modulan cinasas |
HUE050506T2 (hu) | 2015-05-06 | 2020-12-28 | Plexxikon Inc | Kinázokat moduláló vegyület szilárd formái |
WO2016191303A1 (en) | 2015-05-22 | 2016-12-01 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
US9814714B2 (en) | 2015-05-22 | 2017-11-14 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
MX2018003432A (es) | 2015-09-21 | 2018-06-08 | Plexxikon Inc | Compuestos heterociclicos y usos de los mismos. |
MX2018006856A (es) | 2015-12-07 | 2018-08-01 | Plexxikon Inc | Compuestos y metodos para modulacion de la quinasa, e indicaciones de los mismos. |
TWI750645B (zh) * | 2015-12-23 | 2021-12-21 | 美商亞奎里公司 | 四氫哌喃基胺基-吡咯並嘧啶酮和使用彼之方法 |
SI3882250T1 (sl) * | 2015-12-23 | 2023-07-31 | Arqule, Inc. | Tetrahidropiranil amino-pirolopirimidinon za uporabo pri zdravljenju z BTK posredovanih motenj |
TWI694077B (zh) * | 2015-12-23 | 2020-05-21 | 美商亞闊股份有限公司 | 四氫哌喃基胺基-吡咯並嘧啶酮和使用彼之方法 |
US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
US20190083460A1 (en) * | 2016-03-16 | 2019-03-21 | Zeno Royalties & Milestones, LLC | Analgesic compounds |
EP3430005B1 (en) | 2016-03-16 | 2021-12-08 | Plexxikon Inc. | Compounds and methods for kinase modulation and indications therefore |
CN107722013B (zh) * | 2016-08-11 | 2021-01-12 | 中国科学院上海药物研究所 | 去氮嘌呤类化合物及其药物组合物、制备方法和用途 |
KR20190035925A (ko) | 2016-08-24 | 2019-04-03 | 아르퀼 인코포레이티드 | 아미노-피롤로피리미디논 화합물 및 이의 사용 방법 |
TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ido及tdo調節之化合物及方法以及其適應症 |
JP2018047145A (ja) * | 2016-09-23 | 2018-03-29 | 株式会社三共 | スロットマシン |
JP2018047146A (ja) * | 2016-09-23 | 2018-03-29 | 株式会社三共 | スロットマシン |
KR20180051220A (ko) * | 2016-11-08 | 2018-05-16 | 주식회사 대웅제약 | 신규한 피롤로피리미딘 유도체 및 이를 포함하는 약학적 조성물 |
JP7193460B2 (ja) | 2016-12-23 | 2022-12-20 | プレキシコン インコーポレーテッド | Cdk8調節およびその適応症のための化合物および方法 |
WO2018175311A1 (en) | 2017-03-20 | 2018-09-27 | Plexxikon Inc. | Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
WO2018226846A1 (en) | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Compounds and methods for kinase modulation |
CN107298679B (zh) * | 2017-06-29 | 2019-03-01 | 上海吉尔多肽有限公司 | 一种5-氯-1h-吡咯并[2,3-b]吡啶-4-胺的合成方法 |
CA3070505C (en) | 2017-07-25 | 2023-09-26 | Plexxikon Inc. | Formulations of a compound modulating kinases |
JP2020536917A (ja) | 2017-10-13 | 2020-12-17 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼを調節するための化合物の固体形態 |
CN112165958A (zh) | 2017-10-27 | 2021-01-01 | 普莱希科公司 | 调制激酶的化合物的制剂 |
JP2021518367A (ja) | 2018-03-20 | 2021-08-02 | プレキシコン インコーポレーテッドPlexxikon Inc. | Idoおよびtdo調節のための化合物および方法、ならびにそれらのための兆候 |
MA52494A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Formes solides d'un inhibiteur de fgfr et leurs procédés de préparation |
EP3788046A1 (en) | 2018-05-04 | 2021-03-10 | Incyte Corporation | Salts of an fgfr inhibitor |
CN108456212A (zh) * | 2018-05-30 | 2018-08-28 | 杨文思 | 一种化合物或其溶剂合物,或前体,或它们的药学上可接受的盐、药物及其用途 |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
CN113710668A (zh) | 2019-04-09 | 2021-11-26 | 普莱希科公司 | 用于ep300或cbp调节及其适应症的缩合吖嗪 |
AU2020283597A1 (en) * | 2019-05-31 | 2021-11-25 | Fochon Biosciences, Ltd. | Substituted pyrrolo (2, 3-b) pyridine and pyrazolo (3, 4-b) pyridine derivatives as protein kinase inhibitors |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
EP4045151A1 (en) | 2019-10-14 | 2022-08-24 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
JP7011638B2 (ja) * | 2019-12-16 | 2022-02-10 | アークル インコーポレイテッド | テトラヒドロピラニルアミノ-ピロロピリミジノンおよびその使用の方法 |
RU2747991C1 (ru) * | 2020-02-18 | 2021-05-18 | Аркьюл, Инк. | Тетрагидропиранил амино-пирролопиримидинон и способы его применения |
AU2021261383A1 (en) | 2020-04-23 | 2022-11-17 | Opna Bio SA | Compounds and methods for CD73 modulation and indications therefor |
CR20230129A (es) | 2020-08-18 | 2023-07-13 | Incyte Corp | Proceso e intermediarios para preparar un inhibidor de jak |
CN117043152A (zh) | 2020-08-18 | 2023-11-10 | 因赛特公司 | 用于制备jak1抑制剂的方法和中间体 |
US11628176B2 (en) | 2020-08-21 | 2023-04-18 | Opna Bio SA | Combinational drug therapies |
CN116490504A (zh) * | 2020-12-07 | 2023-07-25 | 浙江龙传生物医药科技有限公司 | 吡咯并吡啶类化合物及其应用 |
CN114761410B (zh) * | 2021-04-06 | 2023-08-25 | 广州必贝特医药股份有限公司 | 吡咯并嘧啶酮类化合物及其应用 |
WO2022213932A1 (zh) * | 2021-04-06 | 2022-10-13 | 广州必贝特医药股份有限公司 | 吡咯并嘧啶酮类化合物及其应用 |
TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為fgfr抑制劑之三環雜環 |
CN113717053B (zh) * | 2021-09-02 | 2023-10-27 | 合肥利夫生物科技有限公司 | 一种酪氨酸激酶抑制剂关键中间体的合成方法 |
WO2023122938A1 (en) * | 2021-12-28 | 2023-07-06 | Js Innomed Holdings Ltd. | Heterocyclic compounds as shp2 inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5958930A (en) * | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
US20040171062A1 (en) | 2002-02-28 | 2004-09-02 | Plexxikon, Inc. | Methods for the design of molecular scaffolds and ligands |
PT2277551E (pt) * | 2002-09-06 | 2013-08-22 | Cerulean Pharma Inc | Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente |
WO2004024895A2 (en) | 2002-09-16 | 2004-03-25 | Plexxikon, Inc. | Crystal structure of pim-1 kinase |
UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
US20050048573A1 (en) | 2003-02-03 | 2005-03-03 | Plexxikon, Inc. | PDE5A crystal structure and uses |
US20050170431A1 (en) | 2003-02-28 | 2005-08-04 | Plexxikon, Inc. | PYK2 crystal structure and uses |
US20050079548A1 (en) | 2003-07-07 | 2005-04-14 | Plexxikon, Inc. | Ligand development using PDE4B crystal structures |
US7348338B2 (en) | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
EP1648867B1 (en) | 2003-07-17 | 2013-09-04 | Plexxikon Inc. | Ppar active compounds |
US20050164300A1 (en) | 2003-09-15 | 2005-07-28 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
US20070066641A1 (en) | 2003-12-19 | 2007-03-22 | Prabha Ibrahim | Compounds and methods for development of RET modulators |
EP1696920B8 (en) * | 2003-12-19 | 2015-05-06 | Plexxikon Inc. | Compounds and methods for development of ret modulators |
US7517970B2 (en) | 2003-12-19 | 2009-04-14 | Plexxikon, Inc. | Nucleic acids encoding kinase and phosphatase enzymes, expression vectors and cells containing same |
CN101031293A (zh) | 2004-05-06 | 2007-09-05 | 普莱希科公司 | Pde4b抑制剂及其应用 |
JP2008503473A (ja) | 2004-06-17 | 2008-02-07 | プレキシコン,インコーポレーテッド | C−kit活性を調節する化合物 |
US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
CA2583428A1 (en) | 2004-09-03 | 2006-03-09 | Plexxikon, Inc. | Bicyclic heteroaryl pde4b inhibitors |
EP1819673A2 (en) | 2004-11-30 | 2007-08-22 | Plexxikon, Inc. | Indole derivatives for use as ppar active compounds |
WO2006060535A2 (en) | 2004-11-30 | 2006-06-08 | Plexxikon, Inc. | Indole derivatives for use as ppar active compounds |
US20060160135A1 (en) | 2004-12-08 | 2006-07-20 | Weiru Wang | SF-1 and LRH-1 modulator development |
MX2007014377A (es) | 2005-05-17 | 2008-02-06 | Plexxikon Inc | Inhibidores de proteina cinasa de derivados de pirrol (2,3-b) piridina. |
TWI522337B (zh) | 2005-06-22 | 2016-02-21 | 普雷辛肯公司 | 用於激酶調節的化合物及方法及其適應症 |
US20080234349A1 (en) | 2005-09-07 | 2008-09-25 | Jack Lin | PPAR active compounds |
CA2621406A1 (en) | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | Pparactive compounds |
SG165362A1 (en) | 2005-09-07 | 2010-10-28 | Plexxikon Inc | Ppar active compounds |
BRPI0716944A2 (pt) * | 2006-09-19 | 2013-09-17 | Novartis Ag | biomarcadores de modulaÇço alvo, eficÁcia, diagnàstico, e/ou prognàstico para inibidores de raf |
WO2008063888A2 (en) * | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
CN101641351A (zh) | 2006-12-21 | 2010-02-03 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
RU2009137190A (ru) | 2007-03-08 | 2011-04-20 | Плексксикон, Инк. (Us) | Соединения, обладающие активностью в отношении ppar |
PE20090159A1 (es) | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
SG183036A1 (en) | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
PE20091846A1 (es) * | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2009152083A1 (en) | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | 5h-pyrr0l0 [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor |
US8110576B2 (en) | 2008-06-10 | 2012-02-07 | Plexxikon Inc. | Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications |
AU2010224184A1 (en) * | 2009-03-11 | 2011-09-29 | Plexxikon, Inc. | Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of Raf kinases |
PE20120184A1 (es) | 2009-03-11 | 2012-03-28 | Plexxikon Inc | Derivados del pirrolo[2,3-b]piridina para la inhibicion de las proteinas quinasas raf |
WO2010111527A1 (en) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
MX349923B (es) | 2009-04-03 | 2017-08-21 | Hoffmann La Roche | Composiciones del ácido propano-1-sulfónico {3-[5-(4-cloro-fenil)- 1h-pirrolo [2,3-b]-piridina-3-carbonil]-2,4-difluoro-fenil]-amida y el uso de las mismas. |
SG175877A1 (en) | 2009-05-04 | 2011-12-29 | Plexxikon Inc | Compounds and methods for inhibition of renin, and indications therefor |
TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
ES2633317T3 (es) | 2009-11-06 | 2017-09-20 | Plexxikon, Inc. | Compuestos y métodos para la modulación de quinasas, e indicaciones para ello |
WO2011062939A1 (en) | 2009-11-18 | 2011-05-26 | Novartis Ag | Methods and compositions for treating solid tumors and other malignancies |
BR112012011792A2 (pt) | 2009-11-18 | 2015-10-13 | Plexxikon Inc | "compostos e métodos para modulação de quinases, e indicações para os mesmos" |
US8399678B2 (en) | 2009-11-18 | 2013-03-19 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dabigatran etexilate |
RU2012131373A (ru) | 2009-12-23 | 2014-01-27 | Плексксикон, Инк. | Соединения и способы модулирования киназы, а также показания для такого модулирования |
TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
US8642606B2 (en) | 2010-09-29 | 2014-02-04 | Plexxikon Inc. | ZAP-70 active compounds |
MY162950A (en) | 2011-02-07 | 2017-07-31 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
RU2631487C2 (ru) | 2011-05-17 | 2017-09-22 | Плексксикон Инк. | Модуляция киназ и показания к её применению |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
ES2889757T3 (es) | 2012-09-06 | 2022-01-13 | Plexxikon Inc | Compuestos y procedimientos para la modulación de quinasas e indicaciones para estos |
NZ711896A (en) | 2012-12-21 | 2018-04-27 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
AU2014233437B2 (en) | 2013-03-15 | 2018-07-26 | Opna Immuno Oncology, SA | Heterocyclic compounds and uses thereof |
KR20160013028A (ko) | 2013-05-30 | 2016-02-03 | 플렉시콘, 인코퍼레이티드 | 키나제 조정을 위한 화합물 및 그에 대한 적응증 |
-
2010
- 2010-11-18 BR BR112012011792A patent/BR112012011792A2/pt not_active IP Right Cessation
- 2010-11-18 CN CN201610244552.6A patent/CN105906631A/zh active Pending
- 2010-11-18 CA CA2781287A patent/CA2781287C/en active Active
- 2010-11-18 KR KR1020127015004A patent/KR20120097512A/ko not_active Application Discontinuation
- 2010-11-18 SG SG10201407718WA patent/SG10201407718WA/en unknown
- 2010-11-18 WO PCT/US2010/057293 patent/WO2011063159A1/en active Application Filing
- 2010-11-18 ES ES10832209.0T patent/ES2627911T3/es active Active
- 2010-11-18 RU RU2012125070/04A patent/RU2012125070A/ru not_active Application Discontinuation
- 2010-11-18 US US12/949,741 patent/US8673928B2/en active Active
- 2010-11-18 EP EP10832209.0A patent/EP2501236B1/en active Active
- 2010-11-18 MY MYPI2012002212A patent/MY156210A/en unknown
- 2010-11-18 CN CN2010800616210A patent/CN102740698A/zh active Pending
- 2010-11-18 AU AU2010321883A patent/AU2010321883A1/en not_active Abandoned
- 2010-11-18 PE PE2012000671A patent/PE20121335A1/es not_active Application Discontinuation
- 2010-11-18 NZ NZ599872A patent/NZ599872A/en not_active IP Right Cessation
- 2010-11-18 JP JP2012540066A patent/JP2013511541A/ja active Pending
- 2010-11-18 MX MX2012005827A patent/MX2012005827A/es active IP Right Grant
-
2012
- 2012-05-03 IL IL219567A patent/IL219567A0/en unknown
- 2012-05-17 CO CO12081901A patent/CO6551689A2/es unknown
- 2012-05-18 CL CL2012001303A patent/CL2012001303A1/es unknown
- 2012-06-11 MA MA34954A patent/MA33811B1/fr unknown
-
2014
- 2014-03-17 US US14/216,980 patent/US9617267B2/en active Active
-
2016
- 2016-01-28 AU AU2016200485A patent/AU2016200485B2/en active Active
- 2016-04-26 JP JP2016088438A patent/JP6194389B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
KR20120097512A (ko) | 2012-09-04 |
AU2010321883A1 (en) | 2012-05-31 |
AU2016200485A1 (en) | 2016-02-18 |
PE20121335A1 (es) | 2012-10-12 |
CA2781287C (en) | 2018-07-31 |
CN102740698A (zh) | 2012-10-17 |
NZ599872A (en) | 2014-08-29 |
CL2012001303A1 (es) | 2012-10-05 |
CA2781287A1 (en) | 2011-05-26 |
US9617267B2 (en) | 2017-04-11 |
EP2501236B1 (en) | 2017-03-29 |
EP2501236A1 (en) | 2012-09-26 |
CN105906631A (zh) | 2016-08-31 |
EP2501236A4 (en) | 2013-05-15 |
MA33811B1 (fr) | 2012-12-03 |
US20140288070A1 (en) | 2014-09-25 |
JP2016185958A (ja) | 2016-10-27 |
MY156210A (en) | 2016-01-29 |
US20110152258A1 (en) | 2011-06-23 |
WO2011063159A1 (en) | 2011-05-26 |
IL219567A0 (en) | 2012-06-28 |
JP6194389B2 (ja) | 2017-09-06 |
RU2012125070A (ru) | 2013-12-27 |
CO6551689A2 (es) | 2012-10-31 |
ES2627911T3 (es) | 2017-08-01 |
JP2013511541A (ja) | 2013-04-04 |
US8673928B2 (en) | 2014-03-18 |
SG10201407718WA (en) | 2015-01-29 |
MX2012005827A (es) | 2012-06-19 |
AU2016200485B2 (en) | 2017-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012011792A2 (pt) | "compostos e métodos para modulação de quinases, e indicações para os mesmos" | |
BR112012015745A2 (pt) | compostos e métodos para a modulação de quinase, e indicações dos mesmos | |
WO2010009342A3 (en) | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors | |
CL2011001863A1 (es) | Compuestos derivados de fenilaminopirimidinas, inhibidores de quinasa del linfoma anaplastico; composicion farmaceutica; combinacion farmacologica; y su uso en el tratamiento de trastornos proliferativos tales como linfoma, osteosarcoma, melanoma o tumor de mama, renal y de prostata, entre otros (divisional solicitud 3552-07). | |
UY30892A1 (es) | Inhibidores de la actividad akt | |
CL2007001269A1 (es) | Compuestos derivados de heterociclos de nitrogeno, moduladores de vias de hedgehog; y uso para el tratamiento de cancer pancreatico, cancer de prostata, meduloblastoma, carcinoma celular basal y cancer pulmonar de celula pequena. | |
ATE524459T1 (de) | Pyrazolederivate und ihr einsatz als hemmer von cyclinabhängigen kinasen | |
EA201000094A1 (ru) | Производные пиримидинил-пиридазинона | |
BR112015012536A2 (pt) | tratamento de câncer com inibidores heterocíclicos da glutaminase | |
NO20075245L (no) | Eliminasjon av heterogen eller blandet cellepopulasjon i tumorer | |
TW200728285A (en) | Diacylindazole derivatives as inhibitors of lipases and phospholipases | |
BR112012012694A2 (pt) | "derivados de naftiridina e uso dos mesmos como inibidores de cinase" | |
BRPI0914091A2 (pt) | "igg variante, composição farmacêutica, kit, método para tratar em tumor, método para inibir atividade de vegf, método para modular permeabilidade vascular e método para inibir ou evitar crescimento de células de câncer" | |
EA201001005A1 (ru) | Производные 2-бензилпиридазинона в качестве ингибиторов мет киназы | |
BRPI0915105A2 (pt) | composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer | |
NO20082960L (no) | Ligander med bindingsspesifisitet for VEGF og/eller EGFR og fremgangsmater for anvendelse derav | |
MX2011011737A (es) | Compuestos y metodos para la modulacion de las quinasas e indicaciones de los mismos. | |
MX354402B (es) | Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos. | |
CL2007002640A1 (es) | Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2007002642A1 (es) | Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2007002062A1 (es) | Compuestos derivado de [1,2,4]triazolo[4,3-a]piridina, inhibidores de quinasa; composicion farmaceutica; y su uso en el tratamiento del cancer. | |
ATE432281T1 (de) | Pyrrolotriazin-kinasehemmer | |
WO2010031056A3 (en) | Methods and compositions for modulating ire1, src, and abl activity | |
BR112012027197A2 (pt) | combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas | |
WO2008005281A3 (en) | Genes associated with chemotherapy response and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |